NeurAxis, a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, before the market opens. The company will also host a conference call at 9:00 am ET that day to discuss the results and provide a business update. NeurAxis focuses on its IB-Stim technology, FDA-cleared for treating functional abdominal pain related to IBS and other conditions, with ongoing clinical trials for additional uses. This update is important for investors tracking the company's progress and adoption of its therapies.
UBS Group AG has notified Bang & Olufsen A/S that its shareholding and voting rights have dropped below the 5% threshold, holding 4.85% as of July 8, 2026. This update is in accordance with the Danish Capital Markets Act, which requires disclosure wh...
Assassin’s Creed Black Flag Resynced, a remake of the 2013 original, sold 2 million copies on its first day, marking a strong launch for Ubisoft. The game achieved the highest concurrent player count ever for the franchise on Steam and topped Twitch ...
VKNG Digital, founded by marketing expert Dave Anderson, has launched to provide high-quality SEO and PPC strategies to small and medium-sized businesses in Lancashire. The agency aims to bridge the gap where smaller businesses often lack access to e...
Traders on the Polymarket prediction market estimate only a 21% probability that Bitcoin's price will reach $70,000 before the end of July. This low confidence reflects cautious market sentiment about a near-term surge in Bitcoin's value. Investors m...
Salesforce (CRM) is currently trading at a low trailing free cash flow multiple of about 11x and a forward multiple near 9.6x, reflecting market concerns over SaaS industry challenges and AI disruption. Despite this, Salesforce completed a significan...
